GRIK1 Genotype Moderates Topiramate's Effects on Daily Drinking Level, Expectations of Alcohol's Positive Effects, and Desire to Drink

We (Kranzler et al. 2014) reported that topiramate 200 mg/day reduced heavy drinking days and increased abstinent days in 138 heavy drinkers whose treatment goal was to reduce drinking to safe levels. In that 12-week, placebo-controlled study, we measured drinking using the Timeline Follow-back meth...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Kranzler, Henry R., Armeli, Stephen, Feinn, Richard, Tennen, Howard, Gelernter, Joel, Covault, Jonathan
פורמט: Artigo
שפה:Inglês
יצא לאור: 2014
נושאים:
Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC4161658/
https://ncbi.nlm.nih.gov/pubmed/24786948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1017/S1461145714000510
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים